Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Microplastics (MPs) are pervasive in several ecosystems and have the potential to infiltrate multiple aspects of human life through ingestion, inhalation and dermal exposure, thus eliciting substantial concerns regarding their potential implications for human health. Whilst initial research has documented the effects of MPs on disease development across multiple physiological systems, MPs may also facilitate tumor progression by influencing the tumor microenvironment (TME). This evolving focus underscores the growing interest in the role of MPs in tumorigenesis and their interactions within the TME. In the present review, the relationship between MPs and the TME is comprehensively assessed, providing a detailed analysis of their interactions with tumor cells, stromal cells (including macrophages, fibroblasts and endothelial cells), the extracellular matrix and inflammatory processes. Recommendations for future research directions and strategies to address and reduce microplastic pollution are proposed.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11877014PMC
http://dx.doi.org/10.3892/ol.2025.14939DOI Listing

Publication Analysis

Top Keywords

tumor microenvironment
8
mps
5
role microplastics
4
tumor
4
microplastics tumor
4
microenvironment review
4
review microplastics
4
microplastics mps
4
mps pervasive
4
pervasive ecosystems
4

Similar Publications

Single-Cell RNA Sequencing Reveals Potential Mechanism of RUNX3 Reshaping Tumor Microenvironment in Non-small-cell Lung Cancer.

Ann Surg Oncol

September 2025

Department of Thoracic Surgery, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian Province, China.

Background: RUNX3 acts as a tumor suppressor gene in non-small-cell lung cancer (NSCLC), yet its specific biological mechanism is still unclear. This study aimed to uncover tumor microenvironment (TME) changes in NSCLC with varying RUNX3 expression statuses through single-cell RNA sequencing.

Patients And Methods: In total, seven patients with NSCLC with detailed pathological data were involved, with three both paracancerous and cancerous tissue samples.

View Article and Find Full Text PDF

KRAS mutations in Non-Small Cell Lung Cancer: translational aspects, current therapies and challenges for future research.

Crit Rev Oncol Hematol

September 2025

Unit of Cancer Genetics, Institute of Genetic & Biomedical Research (IRGB), National Research Council (CNR), Traversa La Crucca n. 3, 07100, Sassari, Italy; Immuno-Oncology & Targeted Cancer Biotherapies, University of Sassari, Viale San Pietro 43, 07100, Sassari, Italy. Electronic address: gpalmier

Mutations in the KRAS gene are prominent oncogenic drivers in non-small cell lung cancer (NSCLC), with multiple pathophysiological, clinical and prognostic implications. Although historically considered an "undruggable" target, recent research led to the development of specific KRAS-G12C inhibitors, like sotorasib and adagrasib which are currently approved for clinical use in patients affected by advanced NSCLC. However, the clinical utility of these drugs is often limited by resistance development through several biological mechanisms, including additional KRAS mutations, activation of compensatory pathways and metabolic reprogramming.

View Article and Find Full Text PDF

Role of PAI-1 in the progression and treatment resistance of non-small cell lung cancer.

Biomed J

September 2025

Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University. Electronic address:

Background: Lung cancer is the leading cause of cancer-related mortality worldwide. Although immune checkpoint inhibitors (ICIs), chemotherapy, and molecular targeted therapies have improved survival rates, therapeutic resistance remains a major barrier to curative outcomes. Recently, plasminogen activator inhibitor-1 (PAI-1) has been implicated in lung cancer progression and treatment resistance.

View Article and Find Full Text PDF

Glioblastoma multiforme (GBM) is a rapidly progressing brain malignancy, with its progression closely tied to a hypoxic microenvironment. Hypoxia-inducible factor-1α (HIF-1α) acts as a vital regulator in tumor adaptation to low oxygen levels, and its relationship with the Wnt/β-catenin signaling pathway exerts significant functions in the malignant properties of GBM. In this research, Western blot and qRT-PCR were applied to check β-catenin and HIF-1α expression in GBM.

View Article and Find Full Text PDF

Polysaccharide copolymeric conjugates and their applications in targeted cancer therapy.

Int J Biol Macromol

September 2025

Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Mumbai, 400019, India. Electronic address:

Polysaccharide copolymers Conjuates have surfaced as a versatile foundation in the development of advanced smart drug delivery systems, owing to their inherent biocompatibility, biodegradability, and capacity for chemical modification. This review brings into focus the recent advances in co-polymeric drug delivery systems based on naturally occurring polysaccharides like chitosan, alginate, dextran, hyaluronic acid, pullulan, guar gum, xanthan gum, agarose, gellan gum, and starch. Their structural malleability and functionalization capabilities are emphasized to engineer therapeutic payload stability, bioavailability, and controlled release.

View Article and Find Full Text PDF